| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
Glatiramer acetate (GA) therapy of patients with multiple sclerosis (MS) represents a unique setting in which in vivo Th2 deviation of T cells is consistently observed and associated with clinical benefit in a human autoimmune disease. We postulated that APCs are important targets of GA therapy and demonstrate that treatment of MS patients with GA reciprocally regulates the IL-10/IL-12 cytokine network of monocytes in vivo. We further show that Th1- or Th2-polarized GA-reactive T cells isolated from untreated or treated MS patients mediate type 1 and 2 APC differentiation of human monocytes, based on their ability to efficiently induce subsequent Th1 and Th2 deviation of naive T cells, respectively. These observations are extended to human microglia, providing the first demonstration of type 2 differentiation of CNS-derived APCs. Finally, we confirm that the fundamental capacity of polarized T cells to reciprocally modulate APC function is not restricted to GA-reactive T cells, thereby defining a novel and dynamic positive feedback loop between human T cell and APC responses. In the context of MS, we propose that GA therapy results in the generation of type 2 APCs, contributing to Th2 deviation both in the periphery and in the CNS of MS patients. In addition to extending insights into the therapeutic mode of action of GA, our findings revisit the concept of bystander suppression and underscore the potential of APCs as attractive targets for therapeutic immune modulation.
This article has been cited by other articles:
|
|
 |
|
  H. Li, G.-X. Zhang, Y. Chen, H. Xu, D. C. Fitzgerald, Z. Zhao, and A. Rostami CD11c+CD11b+ Dendritic Cells Play an Important Role in Intravenous Tolerance and the Suppression of Experimental Autoimmune Encephalomyelitis J. Immunol., August 15, 2008; 181(4): 2483 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF]
|
|
|
|
|
|
T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 663 - 670. [Abstract] [PDF]
|
|
|
|
|
|
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168. [Abstract] [PDF]
|
|
|
|
|
|
O. Khan, Y. Shen, C. Caon, F e. Bao, W. Ching, M. Reznar, A. Buccheister, J. Hu, Z. Latif, A. Tselis, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 646 - 651. [Abstract] [PDF]
|
|
|
|
|
|
N Arbour, E Rastikerdar, E McCrea, Y Lapierre, J Dorr, A Bar-Or, and J P Antel Upregulation of TRAIL expression on human T lymphocytes by interferon b and glatiramer acetate Multiple Sclerosis, December 1, 2005; 11(6): 652 - 657. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Wiendl, U. Feger, M. Mittelbronn, C. Jack, B. Schreiner, C. Stadelmann, J. Antel, W. Brueck, R. Meyermann, A. Bar-Or, et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity Brain, November 1, 2005; 128(11): 2689 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Karandikar and M. K. Racke Glatiramer Acetate Therapy: The Plot Thickens Arch Neurol, June 1, 2005; 62(6): 858 - 859. [Full Text] [PDF]
|
|
|
|
|
|
R. Allie, L. Hu, K. M. Mullen, S. Dhib-Jalbut, and P. A. Calabresi Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy Arch Neurol, June 1, 2005; 62(6): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Magnus, B. Schreiner, T. Korn, C. Jack, H. Guo, J. Antel, I. Ifergan, L. Chen, F. Bischof, A. Bar-Or, et al. Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS J. Neurosci., March 9, 2005; 25(10): 2537 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
